heat shock factor binding protein 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored HSBP1P2 profile across patient tissues and cancer cell-line models. HSBP1P2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, HSBP1P2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, HSBP1P2 RNA expression shows 6,651 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, COAD, and STAD as cancer lineages where HSBP1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSBP1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSBP1P2 survival associations across molecular data types. HSBP1P2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSBP1P2 RNA expression–survival associations across cancer types. High HSBP1P2 expression shows unfavorable associations in UCS, KIRC, UVM, CHOL, THYM and THCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for HSBP1P2 RNA expression.
This table summarizes HSBP1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HSBP1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSBP1P2 shows lower tumor expression in LIHC, KIRP, CHOL and KICH and higher tumor expression in COAD and PRAD. The COAD box plot shows higher HSBP1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.507, t-test p < 0.001).
This table shows molecular features associated with HSBP1P2 in patient tissues and cancer cell lines. In patient samples, HSBP1P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
